Karin Karin Loré

This study is testing how well the approved RSV vaccine Arexvy works in adults aged 80 and older compared to those aged 60-65. Researchers want to see if the vaccine produces a strong immune response in the most elderly and frail populations, who are at highest risk for severe RS…